服用绥美凯能活多久？

(Dolutegravir tablets) consists of three drugs: dolutegravir 50mg (dolutegravir) + abacavir 0.6g (abacavir) + lamivudine 0.3g (lamivudine). It is used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir. Clinically, it is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). Clinically, it is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV).

In 2015, a clinical application was submitted for dolutea palamid tablets in China; on January 20, 2017, it applied for import and obtained priority review qualification; on August 1, 2017, it was approved by the CFDA. At present, dolutea palamid tablets have been approved for marketing in 50 countries and regions, and are recommended by many European and American academic institutions and guidelines as the first-line first-line treatment for patients with HIV infection. How long can patients live after taking Suimeikai?

There is no accurate data on how long AIDS patients can live after taking Suimeikan. Currently, there is no accurate data in clinical research, because each AIDS patient's condition is different and the absorption of drugs is also different, so the survival time is also different.

Suimeikai should be taken under the guidance of a physician with experience in HIV infection. For adults and adolescents, the recommended dose of Trimax is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. If the patient misses a dose of SuimeiKai and it is more than 4 hours before the next dose, he should take it as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.